Q1 Results 21st July Live: Bajaj Auto, Granules India, Adani Energy, TVS Motor, ATGL, TVS Holdings, CRISIL, Mastek, IndiaMART, Cyient DLM, Sagility, Canara Robeco to announce Q1 results, UltraTech, Pa
Q1 Results Today, 21st July 2026 Live Updates: Find all the latest Q1 results 2026 updates of Bajaj Auto, Adani Energy Solutions, TVS Motor Company, Indian Hotels Company, JSW Infrastructure, Adani Total Gas, Mahindra and Mahindra Financial Services, Anthem Biosciences, Bandhan Bank, Aditya Birla Sun Life AMC, CRISIL, TVS Holdings, Gabriel India, Granules India, Hatsun Agro Products, Sagility, Bharat Coking Coal, Atlanta Electricals, Trident, AAVAS Financiers, IndiaMART InterMESH, Kirloskar Pneumatic Company, MedPlus Health Services, E2E Networks, Arvind Fashions Limited, Mastek, Canara Robeco Asset Management Company, Cyient DLM, Sunteck Realty, MPS, Welspun Specialty Solutions, Ador Welding, Servotech Renewable Power System, Huhtamaki India, InfoBeans Technologies, NIIT, Hindusthan Insulators & Industries, New Delhi Television, Nureca, GAMCO, Riyaasat Lifestyle, Morarka Finance, and Gujarat Cotex
Source articleMultiple Q1 FY27 results due on 21st July across auto, pharma, energy, banking, IT and infrastructure sectors; stock-specific moves expected based on earnings outcomes.
- ›Q1 FY26 results season July 2025
- ›Q3 FY26 results season January 2026
- ›Q2 FY26 results season October 2025
- Novartis (NVS) Secures $575M Licensing Deal with Abogen Biosciences for Innovative mRNA TherapyImpact 2/10 · Pharmaceuticals · Biotechnology
- Legend Biotech Corp (LEGN) Director Sanders Corazon (Corsee) D. Sells 27,370 SharesImpact 2/10 · Pharmaceuticals · Biotechnology
- Subsea 7 S.A. (SUBCY) Q2 2026 Earnings Call TranscriptImpact 2/10 · Oil & Gas · Energy · Offshore Services
- AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig AlfaImpact 2/10 · Pharmaceuticals · Biotechnology
- MiMedx outlines 2027 revenue well in excess of $400M with over 20% adjusted EBITDA margin following planned Sanara deal (NASDAQ:MDXG)Impact 2/10 · Healthcare · Pharmaceuticals